Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-07-22 7:38 pm Sale |
2025-07-18 | 13D | ARS Pharmaceuticals, Inc. SPRY |
James E. Flynn | 8,633,537 8.790% |
-1,090,971 (-11.22%) |
Filing History |
| 2025-07-11 08:19 am Purchase |
2025-07-07 | 13G | Cogent Biosciences, Inc. COGT |
James E. Flynn | 9,053,118 6.490% |
6,086,773 (+205.19%) |
Filing History |
| 2025-07-02 08:24 am Sale |
2025-07-02 | 13D | ARS Pharmaceuticals, Inc. SPRY |
James E. Flynn | 9,724,508 9.900% |
-790,149 (-7.51%) |
Filing History |
| 2025-06-11 5:38 pm Purchase |
2025-06-06 | 13G | Vera Therapeutics, Inc. VERA |
James E. Flynn | 3,348,117 5.250% |
3,348,117 (New Position) |
Filing History |
| 2025-05-13 8:50 pm Sale |
2025-03-31 | 13G | Owens & Minor, Inc. OMI |
James E. Flynn | 0 0.000% |
-5,229,779 (Position Closed) |
Filing History |
| 2025-05-13 8:50 pm Purchase |
2025-03-31 | 13G | Indivior PLC INDV |
James E. Flynn | 10,567,160 8.470% |
1,684,000 (+18.96%) |
Filing History |
| 2025-05-13 8:50 pm Sale |
2025-03-31 | 13G | Embecta Corp. EMBC |
James E. Flynn | 2,720,535 4.660% |
-354,800 (-11.54%) |
Filing History |
| 2025-05-13 8:49 pm Sale |
2025-03-31 | 13G | MALLINCKRODT PLC SHS MNKTQ |
James E. Flynn | 804,259 4.070% |
-655,974 (-44.92%) |
Filing History |
| 2025-03-24 7:57 pm Sale |
2025-03-20 | 13D | ARS Pharmaceuticals, Inc. SPRY |
James E. Flynn | 10,514,657 10.720% |
-563,270 (-5.08%) |
Filing History |
| 2025-03-03 7:04 pm Purchase |
2025-02-27 | 13D | BiomX Inc. PHGE |
James E. Flynn | 15,558,445 9.990% |
0 (+0.00%) |
Filing History |
| 2025-02-25 9:18 pm Sale |
2025-02-21 | 13D | Singular Genomics Systems, Inc. OMIC |
James E. Flynn | 1,000 100.000% |
-248,495 (-99.60%) |
Filing History |
| 2025-02-13 09:40 am Sale |
2025-02-13 | 13G | DocGo Inc. DCGO |
James E. Flynn | 5,051,500 4.950% |
-4,014,638 (-44.28%) |
Filing History |
| 2025-02-13 09:39 am Purchase |
2024-12-31 | 13G | Indivior PLC INDV |
James E. Flynn | 8,883,160 7.160% |
1,519,950 (+20.64%) |
Filing History |
| 2025-02-13 08:59 am Sale |
2024-12-31 | 13G | Ventyx Biosciences, Inc. VTYX |
James E. Flynn | 534,737 0.760% |
-6,180,764 (-92.04%) |
Filing History |
| 2025-02-13 08:58 am Sale |
2024-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
James E. Flynn | 0 0.000% |
-4,133,000 (Position Closed) |
Filing History |
| 2025-02-13 08:57 am Sale |
2024-12-31 | 13G | Kura Oncology, Inc. KURA |
James E. Flynn | 0 0.000% |
-5,312,733 (Position Closed) |
Filing History |
| 2025-02-13 08:57 am Sale |
2024-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
James E. Flynn | 3,133,011 2.630% |
-3,096,623 (-49.71%) |
Filing History |
| 2025-02-13 08:56 am Sale |
2024-12-31 | 13G | Alignment Healthcare, Inc. ALHC |
James E. Flynn | 7,304,302 3.810% |
-3,561,211 (-32.78%) |
Filing History |
| 2025-02-13 08:55 am Sale |
2024-12-31 | 13G | Nuvalent, Inc. NUVL |
James E. Flynn | 23,582,278 27.590% |
-1,997,612 (-7.81%) |
Filing History |
| 2025-01-28 5:40 pm Sale |
2025-01-27 | 13D | Acutus Medical, Inc. AFIB |
James E. Flynn | 5,492,725 9.100% |
-4,213,132 (-43.41%) |
Filing History |